drugset
drugset / Trial / NCT04731779

Cannabidiol and Autonomic Function at Rest

NCT04731779 ↗

Phase 0 Completed 18 enrolled Castleton University
RandomizedCrossoverTriple-blindBasic science

Summary

Cannabidiol (CBD) is one of 700 chemicals derived from the Cannabis sativa plant and is both legal and widespread for distribution in the state of Vermont. The central hypothesis of this proposal is that in apparently healthy adults, acute CBD favorably affects the autonomic nervous system and that this will be evident by an increase in heart rate variability. The overall goal is to understand how CBD affects the autonomic and cardiovascular systems at rest, and when perturbed. The investigators will study a narrow age range of adults, administer varying acute doses of CBD, characterize baseline cardiovascular variables, and record responses to autonomic challenge maneuvers. This will provide the framework to assess potential therapies and/or risk factors of CBD, particularly as it relates to healthy individuals. More information that is so widely taken, especially one that targets receptors known to be involved in cardiovascular signaling pathways is imperative.

Timeline

Start
2021-08-30
Primary completion
2021-11-29
Completion
2021-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 25 mg Oral
Subject Cannabidiol Other / unclassified 50 mg Oral
Subject Cannabidiol Other / unclassified 200 mg Oral

Indications

No indication recorded.